The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
The move strengthens GBL’s clinical-stage presence in the United States
Subscribe To Our Newsletter & Stay Updated
